Stephane van Rooijen

Stephane van Rooijen currently serves as the Chief Executive Officer at Flamingo Therapeutics, a company focusing on RNA-targeted therapies for oncology. Previously, Stephane held leadership positions in companies such as Dynacure, Confo Therapeutics, ViroPharma Incorporated, Genzyme, and Arthur D. Little. Stephane holds a Doctor of Medicine (M.D.) degree from KU Leuven, a Master of Business Administration (MBA) degree from Erasmus University Rotterdam, and an MBA-exchange degree from Georgetown University McDonough School of Business. Stephane has a strong background in the medical field and business management.